| Literature DB >> 35204122 |
Ramesh Kumar Saini1, Arina Ranjit2, Kavita Sharma2, Parchuri Prasad3, Xiaomin Shang4, Karekal Girinur Mallikarjuna Gowda5, Young-Soo Keum1.
Abstract
The increased consumption of fruits, vegetables, and whole grains contributes to the reduced risk of many diseases related to metabolic syndrome, including neurodegenerative diseases, cardiovascular disease (CVD), diabetes, and cancer. Citrus, the genus Citrus L., is one of the most important fruit crops, rich in carotenoids, flavonoids, terpenes, limonoids, and many other bioactive compounds of nutritional and nutraceutical value. Moreover, polymethoxylated flavones (PMFs), a unique class of bioactive flavonoids, abundantly occur in citrus fruits. In addition, citrus essential oil, rich in limonoids and terpenes, is an economically important product due to its potent antioxidant, antimicrobial, and flavoring properties. Mechanistic, observational, and intervention studies have demonstrated the health benefits of citrus bioactives in minimizing the risk of metabolic syndrome. This review provides a comprehensive view of the composition of carotenoids, flavonoids, terpenes, and limonoids of citrus fruits and their associated health benefits.Entities:
Keywords: cardiovascular disease (CVD); essential oil; limonene; mandarin; metabolic syndrome; neurodegenerative diseases; nobiletin; orange; polymethoxylated flavones (PMFs); β-citraurin
Year: 2022 PMID: 35204122 PMCID: PMC8868476 DOI: 10.3390/antiox11020239
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
The list of citrus fruit species widely investigated for their composition of bioactive compounds and their health benefits.
| Botanical Name | Common Name |
|---|---|
| Lime, key lime, lumy, ancient Mediterranean citrus | |
| Bitter/sour orange | |
|
| Clementine |
| Montenegrin mandarin | |
| Kumquat | |
| Junos, yuzu | |
| Persian lime | |
| Lemon | |
| Rangpur lime | |
| Pomelo, pummelo | |
| Citron, finger citron | |
| Ponkan | |
| Grapefruit, pink/white grapefruit | |
| Tangelo | |
| Mandarin, tangerine, Phlegraean mandarin, ougan | |
| Tangor | |
| Orange, Valencia orange, blood orange, sweet orange | |
| Satsuma mandarin, Mandarin orange |
List of recently published outstanding reviews on composition and health benefits of citrus bioactive compounds.
| Compounds | Review Highlights | Reference |
|---|---|---|
| Essential oil | Extraction, purification, detection methods, composition, and applications of citrus essential oil | [ |
| Composition of volatile compounds from peel, leaves, and flowers of different citrus species | [ | |
| Flavanones (hesperidin and naringin) | The intestinal fate, bioavailability, intestinal metabolism, and interaction with the gut microbiota | [ |
| Flavones | Sources, antioxidant, anti-inflammatory, antimicrobial, anticancer properties | [ |
| Flavonoids | Chemistry, biosynthesis, composition, extraction techniques, health benefits, and industrial applications | [ |
| Composition, antioxidant evaluation, and regulation of Nrf2-Keap1 pathway by citrus flavonoids | [ | |
| Role of citrus flavonoids in brain health: evidence from preclinical and human studies | [ | |
| Biosynthesis, location, and distribution of flavonoids in citrus plants, factors affecting biosynthesis, and health-promoting properties | [ | |
| In vitro, in vivo, and human studies of citrus flavonoids in minimizing the incidence of inflammatory bowel disease | [ | |
| Antidiabetic potential of 19 citrus flavonoids, including diosmin, hesperidin, hesperetin, naringin, naringenin, nobiletin, neohesperidin, quercetin, rutin, and tangeretin | [ | |
| Therapeutic potential in diabetes and diabetic cardiomyopathy, endothelial dysfunction, atherosclerosis, and platelet function | [ | |
| Chemistry, metabolism, bioavailability, biotransformation and delivery systems, and health benefits | [ | |
| Hesperidin and vitamin C | Antiviral properties against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | [ |
| Naringenin | Antidiabetic properties; in vitro, in vivo, and human studies | [ |
| Combating oxidative stress disorders: cardiovascular disease, diabetes mellitus, neurodegenerative disease, pulmonary disease, cancer, and nephropathy | [ | |
| Nobiletin | Beneficial effects against Alzheimer’s disease (AD) and Parkinson’s disease (PD) | [ |
| Nobiletin, 5-demethylnobiletin, and derivatives | Beneficial effects against colon cancer, pharmacokinetics, and bioavailability | [ |
| Nutrients and bioactive | Description of the genus | [ |
| Nutrients (proteins, lipids, vitamins, minerals, fiber) and bioactive (flavonoids, essential oil, limonoids, carotenoids, synephrine) content, their structural characteristics, and health benefits | [ | |
| Polymethoxyflavones (PMF) | Biological properties against metabolic disorder, atherosclerosis, inflammation, neuroinflammation, cancer, and oxidation | [ |
Figure 1The major flavonoids of citrus fruits.
Figure 2The major carotenoids and apocarotenoids of citrus fruits.
Figure 3The major bioactive compounds (terpenes and limonoids) of citrus essential oil.
Health benefits of citrus fruit bioactive compounds demonstrated using in vitro experimental models.
| Compounds | Experimental System | Disease Target | Mechanism of Action | Reference |
|---|---|---|---|---|
| Flavanone-rich mandarin juice extract (0.001–1 mg/mL) | 6-hydroxydopamine (6-OHDA)-stimulated | Parkinson’s disease (PD) | ↓ROS and NO, restored SOD and CAT activity, ↓caspase 3 activity, ↑Bcl-2 mRNA, ↓p53 and Bax mRNA, restored mitochondrial membrane potential, ↓oxidative DNA damage, balanced α-synuclein, LRRK2, parkin, PINK1, and DJ-1 mRNA levels | [ |
| Flavanones (10 µM) | Caco-2 cells stimulated with IL-1 | Bowel diseases | ↓IL-6, IL-8, and NO release | [ |
| Hesperetin and gardenin A (5–10 µM) | PMA/ | Asthma | ↓ROS and IL-5 production, ↓NFAT activity and IL-5 secretion, ↑HO-1 through ↑Nrf2, PPARγ, PI3K/AKT, or ERK/JNK signaling | [ |
| Limonene (1–100 mg/mL) | Aβ1–42 triggered toxicity in primary cortical neurons | Alzheimer’s disease (AD) | ↓AchE, ROS production, voltage-gated K+ channel KV3.4 hyperfunction, and phosphorylated ERK | [ |
| Limonin, nomilin, and limonexic acid (20–60 µM) | Human pancreatic Panc-28 cells | Cancer (pancreatic) | ↓Cell proliferation (IC50 values < 50 μm after 72 h), ↑cleavage of caspase-3, mitochondrial membrane potential, ↑Bax/Bcl2 expression, and p21, ↓COX-2, NF-κβ, and IL-6 | [ |
| Limonoids (Fortunellon and nomilin; 30 µM) | HeLa cells | Cancer (Cervical) | ↑Adriamycin-dependent cell death | [ |
| Naringenin (62.5–2000 µM) | Human A549 lung epithelial cells and primary human monocyte-derived dendritic cells | Zika virus infection | ↓Replication or assembly of viral particles | [ |
| Naringin- and hesperidin-rich junos peel extract (0.5 mg/mL) | Human lung basal epithelial NCI-H460 cells exposed to H2O2 | Oxidative stress-induced diseases | ↓p53, cytochrome c, and Bax proteins | [ |
| Pectin oligosaccharides (5 mg/mL) | LPS-stimulated human macrophages | Atherosclerosis | ↑Immune responses, ↓TNF-α, IL-6, IL-10, and NF-κβ mRNA, | [ |
| Phase-II flavanone metabolites (2–100 µM) | Pancreatic β-cell MIN6 cells exposed to cholesterol | Oxidative stress-induced diseases | ↓Oxidative biomarkers (superoxide anion, H2O2, and MDA), ↓SOD and GPx, ↑insulin secretion, ↓apoptosis | [ |
| PMF nobiletin (10–50 µM) | LPS-stimulated RAW264.7 cells | Inflammatory diseases | ↓Release of NO, ↓expression of iNOS and COX-2, ↑autophagy, activation of the IL-6/STAT3/FOXO3a signal pathway | [ |
| β-cryptoxanthin from mandarin oranges; IC50—4.5µM (24 h treatment) | HeLa cells | Cancer (cervical) | ↓Bcl-2 mRNA, ↑Bax, caspase-3, -7, and -9 mRNA, nuclear condensation | [ |
The upregulation and downregulation are denoted by upward (↑) and downward (↓) arrows, respectively. Abbreviations are as follows: ABCA1: adenosine triphosphate-binding cassette transporter subfamily A member 1; ABCG1: adenosine triphosphate-binding cassette transporter subfamily G member 1; AChE: acetylcholinesterase; AKT: protein kinase B; Aβ1–42: amyloid β-protein; Bax: B-cell lymphoma 2 (Bcl-2)-associated X protein; Bcl2: B-cell lymphoma 2; CAT: catalase; COX-2: cyclooxygenase-2; DJ: Parkinson disease protein 1; EPO: eosinophil peroxidase; ERK: extracellular signal-regulated kinases; FOXO3a: Forkhead box O3a; GPx: glutathione peroxidase; H2O2: hydrogen peroxide; HeLa: human cervical cancer cells; HMGCR: 3-hydroxy-3-methylglutaryl-coenzyme A reductase; HO-1: Heme oxygenase-1; IL: Interleukin; iNOS: inducible nitric oxide synthase; JNK: c-Jun N-terminal kinases; LPS: lipopolysaccharide; LRRK2: leucine-rich repeat kinase 2; LXRα: liver X receptor-α; MDA: malondialdehyde; MPO: myeloperoxidase; NFAT: nuclear factor of activated T cells; NF-κβ: nuclear factor-kappa β; NO: nitric oxide; Nrf2: nuclear factor-erythroid 2 related factor 2; PI3K: phosphoinositide 3-kinase; PINK1: phosphatase and tensin homolog (PTEN)-induced putative kinase 1; PMA: phorbol 12-myristate 13-acetate; PMF: polymethoxylated flavone; PPARγ: peroxisome proliferator-activated receptor γ; ROS: reactive oxygen species; SOD: superoxide dismutase; STAT3: signal transducer and activator of transcription 3; TNF-α: tumor necrosis factor α.
Health benefits of citrus fruit bioactive compounds demonstrated using the animal models.
| Bioactive and Doses | Experimental System | Disease Target | Mechanism of Action | Reference |
|---|---|---|---|---|
| Auraptene (50 mg/kg), naringin (50 mg/kg) for 14 days | STZ-induced hyperglycemia in C57BL/6 mice | Alzheimer’s disease (AD) | ↓Tau hyperphosphorylation, astroglial activation, and ↑neurogenesis in the hippocampus | [ |
| Citrus concentrate containing 0.086 mg β-cryptoxanthin, 5.69 mg hesperidin, and 7.5 mg pectin for 8 weeks | Wistar male rats fed with high-fructose diet | Metabolic syndrome (type 2 diabetes) | ↓Plasma glucose, glycemia, insulinemia, and LDL-C, VLDL-C, and TG levels, ↑liver retinyl palmitate, and plasma β-cryptoxanthin | [ |
| Coumarin (auraptene, 7.5–30 mg/kg for three days a week for total of 8 weeks) | TAA-induced hepatic fibrosis in male C57BL/6 mice | Hepatic fibrosis (cirrhosis and liver cancer) | ↓Bile acids in liver by increasing their efflux, | [ |
| Coumarin auraptene (5–20 mg/kg) | 17α-Ethinylestradiol (synthetic estrogen) induced cholestasis in male C57BL/6 mice | Estrogen-induced cholestasis | ↑Bile acid transporters (Bsep and Mrp2) mRNA and proteins, ↑Shp and Fgf15, FXR, ↑bile acid metabolism, ↑SULT2A1, ↓Cyp7a1 and Cyp8b1 mRNA, ↓hepatic inflammation (↓TNF-α, IL-1β, and IL-6) | [ |
| Essential oil (0.75% of the diet for 42 weeks) | Male SD rats fed with HFD | Metabolic syndrome (hyperlipidemia) | ↓TC, LDL-C, hepatic TC, TG, and hepatic lipid droplet accumulation, ↓liver FFAs, TG, and CE | [ |
| Essential oil (limonene; daily inhalation for 1.5 and 24 h, for five days) | CUMS male Kunming mice mouse model | Depression | ↑Curiosity, body weight, sucrose preference, 5-HT, DA, NE, BNDF, TrkB, GR, ↓CRF, CORT | [ |
| Flavanone aglycones rich ougan ( | HFD-fed C57BL/6J mice | Metabolic syndrome (obesity) | ↓Weight gain, ↓fat accumulation, ↓liver steatosis, ↑glucose homeostasis and insulin sensitivity, ↑BAT activity, and ↑WAT browning, ↑diversity of gut microbiota | [ |
| Flavanones (eriocitrin and eriodictyol), 25 and 50 mg/kg | BALB/c mice with LPS-induced periodontal disease | Periodontitis | ↓Gingival IL-1β and TNF-α, ↑IL-10, ↓MPO and EPO activity, SOD, ↑CAT and GPx activities, ↓MDA | [ |
| Flavanones (naringin, naringenin, hesperidin, and hesperetin; 100 mg/kg/day for 16 weeks) | ApoE−/− mice | Atherosclerosis | ↑Bile acid synthesis (naringin), | [ |
| Flavonoid-rich bitter/sour orange fruit peel extract (125–500 mg/kg for 3 days) | TNBS-induced IBD in male Sprague/Dawley (SD) rats | IBD | ↓Weight loss and diarrhea, colitis inflammatory cell infiltration, and proinflammatory cytokines (TNF-α, iNOS, COX-2), ↓serum and colon NO and MPO activity | [ |
| Hesperetin (40 mg/kg for 45 days) | STZ-induced diabetes in male albino Wistar strain rats | Diabetes | ↓Plasma glucose, ↑plasma insulin and glycogen, ↑antioxidant system (↑SOD, CAT, GPx), ↑insulin secretion by renovating pancreatic β-cells, ↓dyslipidemia (hepatic cholesterol, FFAs, TG, and PLs), ↓serum levels of ALT, AST, and ALP, ↓renal damage (serum urea, creatinine, and uric acid) | [ |
| Hesperetin (50 mg/kg daily for five weeks) | LPS-induced neuroinflammation C57BL/6 N mice | Alzheimer’s disease (AD) and Parkinson’s disease (PD) | ↓Inflammatory mediators (phosphorylated-NF-κβ, TNF-α, and IL-1), ROS/lipid peroxidation, ↑antioxidant protein (Nrf2 and HO-1), ↓phosphorylated-JNK, Bax, and caspase-3 protein, ↑Bcl-2, ↑synaptic integrity, cognition, and memory processes, ↑ phosphorylated-CREB, PSD-95, and Syntaxin | [ |
| Hesperetin (50 mg/kg/day for 46 days) | STZ-induced diabetes in male Wistar rats | Diabetes-associated testicular injury | ↓Body weight loss, ↓ serum glucose, ↓MDA, ROS, protein carbonyl, DNA fragmentation, and caspase 3 activity, ↑testicular antioxidant system (↑GSH, MMP, FRAP, SOD, CAT, GPx) | [ |
| Hesperidin (100 mg/kg for eight weeks) | Male SD rats fed an obesogenic cafeteria diet | Metabolic syndrome (obesity) | ↓TC, LDL-C, FFAs, MCP-1 | [ |
| Limonene-rich essential oil (0.0765 mL/kg for 7 days) | SD rats with estradiol benzoate and oxytocin-induced uterine contraction | Primary dysmenorrhea (PD) | ↑Antioxidant status markers (SOD,T-AOC, CAT, and GSH), ↓MDA and iNOS, and PGF2α/PGE2 | [ |
| Naringin- and hesperidin-rich | Acrolein-induced pulmonary apoptosis in male C57BL/6J mice | Pulmonary edema and COPD | ↓Cleaved caspase 3, cleaved PARP, Bax and PUMA, p53, Prx-SO3 | [ |
| Pectin oligosaccharides (0.15–0.9 g/kg for 30 days) | Male C57BL/6 mice fed with HFD | Metabolic syndrome | ↓Serum TC, LDL-C, ↓ | [ |
| PMF (nobilitin, tangeritin)-rich extract (30–120 mg/kg) | C57BL/6J male mice fed with HFD | Metabolic syndrome | ↓ | [ |
| PMF (nobilitin, tangeritin, and 5-OH nobiletin)-rich aged chenpi peel extract (0.25 and 0.5% of diet weight for 11 weeks) | Male C57BL/6J mice fed with HFD | Metabolic syndrome (obesity) | ↑Fecal SCFAs (acetic acid and propionic acid), ↑healthy gut microbiota | [ |
| PMF 5-Demethylnobiletin (12 mg per kg) | Azoxymethane/DSS-driven colorectal carcinogenesis in male CD-1 mice | Cancer (colorectal) | ↓Cell proliferation, ↑apoptosis, and ↓mRNA and protein levels of IL-1β, IL-6, and TNF-α in the colon | [ |
| PMF- and HOPMF-rich extract (0.5% of HFD for 16 weeks) | Male C57BL/6 mice fed with HFD | Metabolic syndrome (obesity) | ↓Adipocyte size, adipose tissue weight, and alleviated the total body weight, levels of lipid droplets, and perilipin 1 protein and | [ |
The upregulation and downregulation are denoted by upward (↑) and downward (↓) arrows, respectively. Abbreviations are as follows: 5-HT: 5-hydroxytryptamine; ALP: alkaline phosphatase; ApoE: apolipoprotein E; AST: aspartate aminotransferase; BAT: brown adipose tissue; Bax: B-cell lymphoma 2 (Bcl-2)-associated X protein; BCAA: branched-chain amino acid; Bcl-2: B-cell lymphoma 2; BNDF: brain-derived neurotrophic factor; Bsep: bile salt export pump; CAT: catalase; CE: cholesterol esters; COPD: obstructive pulmonary disease; CORT: corticosterone; COX-2: cyclooxygenase-2; CREB: cAMP response element-binding protein; CRF: corticotropin-releasing factor (CRF); CUMS: chronic unpredictable mild stress; Cyp7a1: cholesterol 7α-hydroxylase; Cyp8b1: sterol-12α-hydroxylase; DA: dopamine; DSS: dextran sulfate sodium; FFA: free fatty acids; FFAs: free fatty acids; Fgf15: fibroblast growth factor 15; FRAP: ferric reducing antioxidant; FXR: farnesoid X receptor; GPx: glutathione peroxidase; GR: glucocorticoid receptor; GSH: glutathione; HFD: high-fat diet;.HO-1: Heme oxygenase; HOPMFs: hydroxy polymethoxyflavones; HSCs hepatic stellate cells; HSCs: hepatic stellate cells; IBD: inflammatory bowel disease; IL: Interleukin; iNOS: inducible nitric oxide synthase; JNK: c-Jun N-terminal kinases; LDL-C: low-density lipoprotein cholesterol (LDL-c); LPS: lipopolysaccharide; MCP-1: monocyte chemoattractant protein 1; MDA: malondialdehyde; MMP: mitochondrial membrane potential; MPO: myeloperoxidase; Mrp2: multidrug-resistance-related protein 2; mTOR: mammalian target of rapamycin; mTORC1: mammalian target of rapamycin (mTOR) complex1; NE: norepinephrine; NF-κβ: nuclear factor-kappa β; NO: nitric oxide; Nrf2: nuclear factor-erythroid 2 related factor 2; P70S6K: phospho-p70 S6 kinase; PARP: poly (ADP-ribose) polymerase; PGE2: prostaglandin E2; PGF2α: prostaglandin F2α;.PLs: phospholipids; PMF: polymethoxyflavones; Prx-SO3: oxidized peroxiredoxin; PSD-95: postsynaptic density protein-95; PUMA: p53 upregulated modulator of apoptosis; ROS: reactive oxygen species; SCFAs: short-chain fatty acids; SD: Sprague Dawley; Shp: small heterodimer partner; SMAα: α-smooth muscle actin; SOD: superoxide dismutase; SREBP-1Sterol regulatory element-binding protein 1; STZ: streptozotocin;SULT2A1: sulfotransferase family 2a member 1; TAA: thioacetamide; T-AOC: total antioxidant capacity; TC: total cholesterol; TG: triglyceride and hepatic lipid droplet accumulation; TGF-β1: transforming growth factor-β1; TNBS: trinitrobenzene sulfonic acid; TNF-α: tumor necrosis factor α; TrkB: tropomyosin receptor kinase B; VLDL-C: very-low-density lipoprotein-cholesterol; WAT: white adipose tissue.